ML Strategies

In 2023, the FDA navigated challenges while achieving significant public health milestones. Member Joanne Hawana and Of Counsel Benjamin Zegarelli highlight key takeaways from the year, addressing multifaceted issues such as CBD regulation, the overhaul of in vitro clinical tests, and the management of manufacturing failures. These pivotal topics underscore the FDA’s proactive approach to evolving healthcare regulations and technological advancements.

Senior VP of ML Strategies John Lushetsky, Private Equity Practice Co-chair Matthew T. Simpson, Member Paul H. Dickerson, and Project Analyst Raj Gambhir delve into the transformative landscape of cross-border supply chains for critical minerals, EV batteries, and semiconductors. Navigating the intricacies of the Inflation Reduction Act, Defense Production Act, and tax credits, the authors highlight how Canadian companies, considered ‘domestic’ under certain legislations, can harness funding and benefits.